SAND-5 RGD

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameSAND-5 RGD

Drug Alias NameErgidinacomplement C5 antibody (ADIENNE)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Recombinant protein

Mechanisms of ActionC5a anaphylatoxin chemotactic receptor antagonists

TargetsC5a anaphylatoxin chemotactic receptor

Therapy Area/IndicationsIschemiaInflammationReperfusion Injury

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesItaly

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesADIENNE Pharma & Biotech SA

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesADIENNE Pharma & Biotech SA

Active IndicationsN/A

Inactive IndicationsIschemiaInflammationReperfusion Injury

Other Information

ATC CodeN/A